Systematic analysis of the molecular pathophysiology of tenosynovitis: promise for using chondroitin sulfate and glucosamine sulfate
| Autor: | I. Yu. Torshin, Alexander Lila, O A Limanova, O. A. Gromova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2020 |
| Předmět: |
Glucosamine Sulfate
Inflammation Osteoarthritis 030204 cardiovascular system & hematology Pharmacology Proinflammatory cytokine 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine Chondroitin sulfate RC346-429 chondroitin sulfate Tenosynovitis glucosamine sulfate business.industry Inflammasome systems biology data mining medicine.disease tenosynovitis Pathophysiology Psychiatry and Mental health Clinical Psychology chemistry Neurology (clinical) Neurology. Diseases of the nervous system medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika, Vol 12, Iss 2, Pp 64-71 (2020) |
| ISSN: | 2310-1342 2074-2711 |
| Popis: | The chondroprotectors glucosamine sulfate (GS) and chondroitin sulfate (CS) show a complex anti-inflammatory effect and therefore may be used in the therapy of many diseases concurrent with osteoarthritis. Objective: to carry out a systematic analysis of the relationship between the molecular pathophysiology of tenosynovitis and the potential mechanisms of pathogenic action of CS/GS in this disease. Material and methods. The texts of 15 097 publications were systemized using the current methods for topographic big data analysis, which had been developed as part of topological and metric approaches to recognition/classification problems. Results and discussion. The investigators created a map showing the molecular pathophysiology of tendosynovitis and including 15 molecular mechanisms and 27 comorbidities and identified mechanisms, through which GS/CS could prevent the development of tenosynovitis, such as inhibition of the effects of proinflammatory cytokines (IL-1, IL-8, γ -interferon, and TNF- α ), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein, NLRP3 inflammasome, NF- κ B and JAK/STAT signaling pathways, and O-glucosamination of proteome proteins. To date, no randomized clinical or cohort (non-interventional) studies of the effects of CS/GS have been conducted in patients with tendosynovitis and comorbidities. However, preclinical studies of GS and CS in the treatment of tendinopathies showed that the drugs had analgesic properties, alleviated chronic inflammation and edema, and improved the maturation of collagen bundles and therefore the mechanical properties of connective tissue in the tendons and ligaments. Conclusion. The experimental and clinical studies indicate that pharmaceutical-grade GS/CS preparations of high standardization are promising in treating tenosynovitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|